Dystrophic epidermolysis bullosa: pathogenesis and clinical features

Leena Bruckner-Tuderman

doi:10.1016/j.det.2009.10.020

Dystrophic epidermolysis bullosa: pathogenesis and clinical features

Dermatol Clin. 2010 Jan;28(1):107-14. doi: 10.1016/j.det.2009.10.020.

Author

Leena Bruckner-Tuderman¹

Affiliation

¹ Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany. bruckner-tuderman@uniklinik-freiburg.de

PMID: 19945622
DOI: 10.1016/j.det.2009.10.020

Abstract

Dystrophic epidermolysis bullosa (DEB) is relatively well understood. Potential therapies are in development. This article describes the pathogenesis and clinical features of DEB. It also describes therapeutic options and the future of molecular therapies.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Dermis / pathology*
Epidermis / pathology*
Epidermolysis Bullosa Dystrophica / etiology*
Epidermolysis Bullosa Dystrophica / pathology*
Epidermolysis Bullosa Dystrophica / therapy
Humans